Matrix‐remodelling‐associated protein 5 (MXRA5) and a fibronectin type III domain containing 1 (FNDC1), associated with ECM, were revealed as novel biomarkers of calcified valves.85 Lately, miRNAs were proposed as innovative biomarkers and therapeutic strategies for aortic valve stenosis, as revealed in a groundbreaking pre‐clinical study using inhibitors of miR‐34a.86, 87, 88. This evidence concerns the gene MXRA5 and stricture.